NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating on Akebia Therapeutics, Inc. (NASDAQ: AKBA)
Aegis Capital has reiterated a ‘Buy’ rating and a price target of $25 on Akebia Therapeutics (NASDAQ: AKBA) following the company’s recent report of financial results for the first quarter ended March 31, 2017. Akebia reported cash, cash equivalents and marketable securities of $251.8 million. Combined with additional upcoming payments, the company said it expects to have resources to fund the current operating plan into the first quarter of 2019. Among other highlights, the analyst noted Akebia’s upcoming milestones, including the top-line results of a phase 2 trial in Japan in the second half of 2017; the initiation of a…







